Lijing Shen

Dr. Lijing Shen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BNBeiwen Ni
Beiwen Ni
GHGan Huang
Gan Huang
HHHonghui Huang
Honghui Huang
TWTing Wang
Ting Wang
XHXiaofeng Han
Xiaofeng Han
JHJian Hou
Jian Hou
Objects: To evaluate the prognostic value of radiomics features extracted from 18F-FDG-PET/CT images and integrated with clinical characteristics and conventional PET/CT metrics in newly diagnosed multiple myeloma (NDMM) patients. Methods: We retrospectively reviewed baseline clinical information and 18F-FDG-PET/CT imaging data of MM patients with 18F-FDG-PET/CT. Multivariate Cox regression models involving different combinations were constructed, and stepwise regression was performed: (1) radiomics features of PET/CT alone (Rad Model); (2) Using clinical data (including clinical/laboratory parameters and conventional PET/CT metrics) only (Cli Model); (3) Combination radiomics features and clinical data (Cli-Rad Model). Model performance was evaluated by C-index and Net Reclassification Index (NRI). Results: Ninety-eight patients with NDMM who underwent 18F-FDG-PET/CT between 2014 and 2019 were included in this study. Combining radiomics features from PET/CT with clinical data showed higher prognostic performance than models with radiomics features or clinical data alone (C-index 0.790 vs. 0.675 vs. 0.736 in training cohort; 0.698 vs. 0.651 vs. 0.563 in validation cohort; AUC 0.761, sensitivity 56.7%, specificity 85.7%, p < 0.05 in training cohort and AUC 0.650, sensitivity 80.0%, specificity78.6%, p < 0.05 in validation cohort) When clinical data was combined with radiomics, an increase in the performance of the model was observed (NRI > 0). Conclusions: Radiomics features extracted from the PET and CT components of baseline 18F-FDG-PET/CT images may become an effective complement to provide prognostic information; therefore, radiomics features combined with clinical characteristic may provide clinical value for MM prognosis prediction.

8 July 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JHJiayu Huang
Jiayu Huang
BSBingyang Shi
Bingyang Shi
SYSuhui Yu
Suhui Yu
MXMengxing Xue
Mengxing Xue
LWLing Wang
Ling Wang
XHXiaoxia Hu
Xiaoxia Hu

26 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KHKang He
Kang He
SXShanshan Xu
Shanshan Xu
LSLijing Shen
Lijing Shen
XCXiaosong Chen
Xiaosong Chen
QXQiang Xia
Qiang Xia
YQYongbing Qian
Yongbing Qian
Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal hyperinflammatory disorder characterized by dysfunctional cytotoxic T and natural killer cells. Liver transplantation is a predisposing factor for HLH. High mortality rates were reported in 40 cases of HLH following liver transplantation in adults and children. Herein, we describe a case of adult HLH triggered by cytomegalovirus (CMV) infection shortly after liver transplantation. The patient was successfully treated with ruxolitinib combined with a modified HLH-2004 treatment strategy. Our case is the first to report the successful use of ruxolitinib with a modified HLH-2004 strategy to treat HLH in a solid organ transplantation recipient.

19 November 2024 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
ASAnqi Song
Anqi Song
BNBeiwen Ni
Beiwen Ni
MTMolian Tang
Molian Tang
YZYiquan Zhou
Yiquan Zhou
XZXiaomin Zhang
Xiaomin Zhang
RXRENYING XU
RENYING XU

27 December 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
MZMinyue Zhang
Minyue Zhang
YCYong-Mei Cai
Yong-Mei Cai
XZXiao-Qing Zhu
Xiao-Qing Zhu
KLKe-Jie Lu
Ke-Jie Lu
LSLijing Shen
Lijing Shen
JDJuan Du
Juan Du
Indolent B-cell non-Hodgkin’s lymphomas (B-NHLs), including follicular lymphoma (FL) and marginal zone lymphoma (MZL), typically demonstrate slow pro

16 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YFYi Fang
Yi Fang
WLWeiwei Lin
Weiwei Lin
LSLijing Shen
Lijing Shen
BNBeiwen Ni
Beiwen Ni
MZMinyue Zhang
Minyue Zhang
JHJian Hou
Jian Hou
Background: Chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) have been used as an effective therapy against relapsed/refractory multiple myeloma (MM). However, the relapse rates in these patients are still high, which may be related to the poor quality of T cells after multiple chemotherapies. The case reported here demonstrated the effectiveness and safety of first-line anti-BCMA CAR-T cell therapy for high-risk MM patients, even in frailty with multiple comorbidities.Case presentation: A 75-year-old woman was diagnosed with biclonal gammopathy and high-risk MM with extramedullary mass in the right caput femoris. The patient was fragile with multiple comorbidities, including pneumonia, left lower limb deep venous thrombosis, and epilepsy secondary to cerebral hemorrhage. Considering the patient’s fragility and comorbidities, commercial equecabtagene autoleucel, a fully human anti-BCMA CAR-T cells, as first-line CAR-T cell therapy, was proposed and accepted by the patient and her family. After one cycle of bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen), she reached very good partial response (VGPR). Then her leukapheresis was performed, and the harvested cells were sent to the manufacturer for preparation. After lymphodepletion was performed using fludarabine and cyclophosphamide (FC) chemotherapy, her equecabtagene autoleucel was transfused. On day 21 after infusion, she achieved stringent complete remission (sCR) with minimal residual disease (MRD) negativity without severe toxicity. The CAR-T cells/CD3+ T cell ratio gradually increased, reaching a maximum of 54.97% on day 14, and gradually decreased, remaining at 0.03% on the 153rd day. The patient received right hip replacement plus pelvic lesion curettage 7 months after CAR-T transfusion due to pain in her right hip, but no MM cells were found in postoperative pathology. Hitherto, her deep remission persisted for 12 months without any maintenance therapy.Conclusion: First-line anti-BCMA CAR-T cell therapy is effective and safe for high-risk MM patients, even in fragile patients with multiple comorbidities.